Press release
ER+/HER2- Breast Cancer Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight
ER+/HER2- Breast Cancer Treatment Market
ER+/HER2- Breast Cancer emerging therapies such as KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others are expected to boost the ER+/HER2- Breast Cancer Market in the upcoming years.
Discover latest insights into our ER+/HER2- Breast cancer market report - https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of the ER+/HER2- Breast Cancer Market Report:
• In 2021, the total number of new breast cancer cases in the United States was 256,431. Among these, postmenopausal breast cancer accounted for 205,145 cases. In the same year, the distribution of breast cancer cases by stage was as follows: 164,116 localized, 74,365 regional, 15,386 distant, and 2,564 with unknown stage. These numbers are expected to rise during the forecast period.
• Among the various subtypes of the disease (localized and regional), ER+/HER2- represented the largest patient group with 147,977 cases, followed by 24,325 cases of triple-negative breast cancer and 20,271 cases of ER+/HER2+. Conversely, HR-/HER2+ had the fewest cases.
• Key ER+/HER2- Breast Cancer companies such as Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and others are evaluating new drugs for ER+/HER2- Breast Cancer to improve the treatment landscape.
• Promising ER+/HER2- Breast Cancer pipeline therapies in various stages of development include KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others.
Key benefits of the ER+/HER2- Breast Cancer market report:
• ER+/HER2- Breast Cancer market report covers a descriptive overview and comprehensive insight of the ER+/HER2- Breast Cancer Epidemiology and ER+/HER2- Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
• The ER+/HER2- Breast Cancer market report provides insights on the current and emerging therapies.
• ER+/HER2- Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
• The ER+/HER2- Breast Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the ER+/HER2- Breast Cancer market.
Got queries? Click here to know more about the ER+/HER2- Breast Cancer Market Landscape https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
ER+/HER2- Breast Cancer Overview
Breast cancer develops when abnormal cancerous cells in the breast grow and multiply uncontrollably, forming a tumor. It typically begins in the breast's ducts or lobules. Cancer cells receive various signals that drive their growth, which can include hormones.
Hormone receptors are proteins that detect hormone signals and instruct the cancer cells to grow. When breast cancer cells are stimulated by estrogen, which promotes tumor growth, it is called estrogen receptor-positive (ER+) breast cancer. Similarly, when cells respond to progesterone, promoting growth, it is termed progesterone receptor-positive (PR+) breast cancer. Breast cancer that is either ER+ or PR+ is classified as hormone receptor-positive (HR+) breast cancer.
On the other hand, hormone receptor-negative (HR-) breast cancer occurs when cancer cells lack hormone receptors. These cells do not rely on estrogen or progesterone to grow.
Another key factor in breast cancer is the human epidermal growth factor receptor 2 (HER2), a gene responsible for regulating cell growth, division, and repair. The HER2 protein acts as a receptor on breast cells. HER2-positive (HER2+) breast cancer tests positive for this protein, and these cancers tend to grow more rapidly and are more likely to spread or recur compared to HER2-negative (HER2-) breast cancer. The HER2 status of a patient is determined through testing for the presence of the HER2 protein.
In HER2- negative breast cancer, cells do not have a significant amount of the HER2 protein on their surface. These cancer cells often grow more slowly and are less likely to spread or come back compared to HER2+ cells. Testing for HER2 can help guide treatment decisions.
ER+/HER2- Breast Cancer Treatment Market
Estrogen receptor (ER) expression is a key factor in predicting the effectiveness of hormonal therapy, as most human breast cancers are hormone-dependent and ER-positive. There are several types of anti-estrogenic treatments available for patients with early, advanced, or metastatic breast cancer, including selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders. However, ongoing clinical research is focused on combining anti-estrogenic therapies with targeted agents that block the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling pathway or the cyclin-dependent kinase 4/6 (CDK4/6) pathway, which regulates the G1/S checkpoint of the cell cycle. These combinations are being studied for patients with hormone receptor-positive breast cancer who have experienced disease recurrence or progression.
Discover how the ER+/HER2- Breast cancer treatment market is growing https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
ER+/HER2- Breast Cancer Market Outlook
Breast cancer is the second most common cancer globally, with estrogen receptor-positive (ER+) breast cancer being the most prevalent type. About two-thirds of breast cancer cases are hormone receptor-positive (HR+), with the majority being ER+. These cancers are driven by estrogen, which stimulates their growth.
The stage of breast cancer is critical for treatment decisions. For women with Stage I, II, or III breast cancer, surgery is usually the primary treatment, often followed by radiation therapy. Chemotherapy, hormone therapy (tamoxifen or aromatase inhibitors), and HER2-targeted drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) are commonly used depending on the tumor's hormone receptor and HER2 status. For Stage I HR+ breast cancer, hormone therapy is typically recommended, while larger tumors may also require chemotherapy. HER2+ cancers generally receive trastuzumab as part of the treatment.
For Stage II breast cancer, systemic therapy (neoadjuvant or adjuvant) is recommended, often before or after surgery. Neoadjuvant therapy can shrink large tumors, allowing for breast-conserving surgery. Stage III cancers often require neoadjuvant chemotherapy, and HER2+ tumors are treated with trastuzumab and sometimes pertuzumab.
Current drugs include tamoxifen, aromatase inhibitors (letrozole, anastrozole, exemestane), luteinizing hormone-releasing hormone analogs (goserelin, leuprolide), and fulvestrant for patients resistant to previous treatments. Sequential hormone therapy is recommended until resistance develops, at which point chemotherapy may be necessary.
The pipeline for ER+/HER2- breast cancer includes several promising drugs in late- and mid-stage development, with key players like Radius Pharmaceuticals (Elacestrant), AstraZeneca (Camizestrant), Roche (Giredestrant), and others working on treatments that may reshape the market in the coming years.
Explore more about ER+/HER2- Breast cancer market @ https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
ER+/HER2- Breast Cancer Marketed Drugs:
• KISQALI (ribociclib): Novartis
• IBRANCE (palbociclib): Pfizer
• AFINITOR (everolimus): Novartis
• LYNPARZA (olaparib): AstraZeneca
ER+/HER2- Breast Cancer Emerging Drugs:
• Elacestrant: Radius Pharmaceuticals
• Giredestrant (RG6171, GDC-9545): Roche
• Camizestrant (AZD9833): AstraZeneca
• LY3484356 (imlunestrant): Eli Lilly
• Lerociclib (EQ132): EQRx
Discover which ER+/HER2- Breast cancer drugs will boost the market in the upcoming years @ https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the ER+/HER2- Breast Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key ER+/HER2- Breast Cancer Companies: Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and others
• Key ER+/HER2- Breast Cancer Therapies: KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others
• ER+/HER2- Breast Cancer Therapeutic Assessment: ER+/HER2- Breast Cancer current marketed and ER+/HER2- Breast Cancer emerging therapies
• ER+/HER2- Breast Cancer Market Dynamics: ER+/HER2- Breast Cancer market drivers and ER+/HER2- Breast Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• ER+/HER2- Breast Cancer Unmet Needs, KOL's views, Analyst's views, ER+/HER2- Breast Cancer Market Access and Reimbursement
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. ER+/HER2- Breast Cancer Patient Share (%) Overview at a Glance
5. ER+/HER2- Breast Cancer Market Overview at a Glance
6. ER+/HER2- Breast Cancer Disease Background and Overview
7. ER+/HER2- Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of ER+/HER2- Breast Cancer
9. ER+/HER2- Breast Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. ER+/HER2- Breast Cancer Emerging Therapies
12. ER+/HER2- Breast Cancer Market Outlook
13. Country-Wise ER+/HER2- Breast Cancer Market Analysis (2019-2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. ER+/HER2- Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about ER+/HER2- Breast Cancer Market Outlook 2032 https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Related Reports:
ER+/HER2- Breast Cancer Pipeline Insights, DelveInsight
https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
"ER+/HER2- Breast Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the ER+/HER2- Breast Cancer market. A detailed picture of the ER+/HER2- Breast Cancer pipeline landscape is provided, which includes the disease overview and ER+/HER2- Breast Cancer treatment guidelines.
Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ER+/HER2- Breast Cancer Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight here
News-ID: 4125015 • Views: …
More Releases from DelveInsight Business Research
Familial Chylomicronemia Syndrome Market to Expand Significantly by 2034, States …
DelveInsight's "Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome…
Generalized Anxiety Disorder Pipeline 2025: Therapies, MOA Insights, and Key Cli …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Generalized Anxiety Disorder pipeline constitutes 12+ key companies continuously working towards developing 15+ Generalized Anxiety Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Generalized Anxiety Disorder Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Generalized Anxiety…
Primary Mitochondrial Myopathies Pipeline 2025: MOA, ROA, FDA-Approved Drugs, an …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Mitochondrial Myopathies pipeline constitutes 4+ key companies continuously working towards developing 4+ Primary Mitochondrial Myopathies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Primary Mitochondrial Myopathies Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Mitochondrial…
Chlamydia Infections Pipeline 2025: Therapies Under Investigation, Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chlamydia Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Chlamydia Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Chlamydia Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
